key: cord-0737118-6zzlmha5
authors: Yu, Hongjie; Yang, Juan; Marziano, Valentina; Deng, Xiaowei; Guzzetta, Giorgio; Zhang, Juanjuan; Trentini, Filippo; Cai, Jun; Poletti, Piero; Zheng, Wen; Wang, Wei; Wu, Qianhui; Zhao, Zeyao; Dong, Kaige; Zhong, Guangjie; Viboud, Cecile; Merler, Stefano; Ajelli, Marco
title: Can a COVID-19 vaccination program guarantee the return to a pre-pandemic lifestyle?
date: 2021-02-09
journal: Res Sq
DOI: 10.21203/rs.3.rs-200069/v1
sha: 8d65f0eb091a8af165c83e6da450b6c9c334e3c0
doc_id: 737118
cord_uid: 6zzlmha5

COVID-19 vaccination programs have been initiated in several countries to control SARS-CoV-2 transmission and return to a pre-pandemic lifestyle. However, understanding when non-pharmaceutical interventions (NPIs) can be lifted as vaccination builds up and how to update priority groups for vaccination in real-time remain key questions for policy makers. To address these questions, we built a data-driven model of SARS-CoV-2 transmission for China. We estimated that, to prevent local outbreaks to escalate to major widespread epidemics, stringent NPIs need to remain in place at least one year after the start of vaccination. Should NPIs be capable to keep the reproduction number (Rt) around 1.3, a vaccination program could reduce up to 99% of COVID-19 burden and bring Rt below the epidemic threshold in about 9 months. Maintaining strict NPIs throughout 2021 is of paramount importance to reduce COVID-19 burden while vaccines are distributed to the population, especially in large populations with little natural immunity.

The novel coronavirus disease 2019 (COVID-19) pandemic is far from over with 48 cases still surging in many countries across the globe 1 . In 2020, epidemic suppression 49 and/or mitigation have relied on non-pharmaceutical interventions (NPIs), including 50 social distancing, school closure, masking, and case isolation. Although effective and 51 widely adopted to limit SARS-CoV-2 transmission and reduce COVID-19 burden, 52 these interventions entail enormous economic costs and negatively affect quality of 53 life 2 . Additionally, in many countries, relaxation of NPIs has led to a resurgence of the 54 epidemic as no location has reached herd immunity thus far 3 -even in Manaus, Brazil 55 where it is estimated that over >70% of the population has been naturally infected, the 56 epidemic is seemingly not over 4 . In this study, we aim to address these questions by using China as a case study. To do 72 so, we build an age-structured stochastic model to simulate SARS-CoV-2 73 transmission in mainland China, based on a susceptible-infectious-removed (SIR) 74 scheme (Extended Data Fig. 1 ). We account for heterogeneous mixing patterns by In the absence of NPIs, the vaccination program is too slow to lower and delay the 104 epidemic ( Fig. 1A) and does not effectively reduce COVID-19 burden. Rt falls below 105 the epidemic threshold (<1) 69 days after the epidemic start (Fig. 1B) , but this is 106 primarily attributable to immunity gained through natural infection rather than 107 vaccination. Indeed, in this time frame, 52.2% of population gets infected, while only 108 6.7% of population has been vaccinated (Fig. 1C) below the epidemic threshold about 9 months after the epidemic start ( Fig. 1) Fig.2-3) . Earlier or more drastic relaxations 132 of NPIs lead to substantial increases in deaths (Extended Data Fig.2-3) . 1,000 individuals), in the absence of NPIs, we estimate that over 7.7 million deaths 159 would still occur (Fig. 3) . Similar patterns are estimated for the number of 160 symptomatic cases, hospitalizations and ICU admissions (Extended Data Fig.4-6) . compare other strategies to that with minimum deaths using rank sum test. E.g., in the 428 context of initial cases=5,000, Rt=1.5 and using mean values of contact patterns and 429 relative susceptibility, the baseline is the optimal strategy to minimize deaths. 432 We developed a model of SARS-CoV-2 transmission and vaccination, based on an while the remaining population is vaccinated as described in Table 2 by considering 568 different orders of prioritization only based on age and disregarding the presence of 569 underlying conditions (SE20: first prioritization to old adults; SE21: first 570 prioritization to working-age groups; SE22: first prioritization to school-age groups).

We explore the impact of 5,000 initial cases on the prioritization strategy (SE23). To The daily age-specific number of deaths in the two subpopulations was computed by 604 applying the age-specific fatality ratio among symptomatic cases (Supplementary File 605 4), delayed by an average time of 13.9 days between symptom onset and death. 12

stochastic model realizations were performed. The outcome of 608 these simulations determined the distributions of the number of symptomatic 609 infections, hospitalizations, ICU admissions, and deaths. 95% confidence intervals 610 were defined as quantiles 0.025 and 0.975 of the estimated distributions

Bayesian approach to estimate Rt from the time series of symptomatic cases by date 612 of symptom onset and the distribution of the serial interval 11 . The methods were

Ethics approval All these data were in the public domain. Ethical review for the re

Further information on research design is available in the Nature Research Reporting

Should the manuscript be accepted, all data and codes will be provided on GitHub

Department of Economic and Social Affairs

Who should be Prioritized for COVID-19 Vaccination in China? A Descriptive 628 Study

Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 630 transmission under intensive contact tracing in Hunan

Transmission heterogeneities, kinetics, and controllability of SARS-CoV-2

Association of Public Health Interventions With the Epidemiology of the COVID-634 19 Outbreak in Wuhan, China

Active case finding with case management: the key to tackling the COVID-19 636 pandemic

Rapid Response to an Outbreak in Qingdao

Xinhua net. The COVID-19 outbreak in Beijing

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected 642

The Central People's Government of the People's Republic of China. COVID-19 vaccine 644 development, priority populations and pricing

Who should be prioritized for COVID-19 vaccination in China? A descriptive 647 study

Dynamic Profile of RT-PCR Findings from 301 COVID-19 Patients in Wuhan, 649 China: A Descriptive Study

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a 651 randomised, double-blind, placebo-controlled, phase 1/2 trial

Influenza vaccine effectiveness against medically-attended influenza illness 654 during the 2012-2013 season in Beijing

The study was supported by grants from the National Science Fund for Distinguished 658

Key Emergency Project of Shanghai Science and 659

National Science Fund for Distinguished 660

commented on the data and its interpretation, 669 revised the content critically. All authors contributed to review and revision and 670 approved the final

has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang 675 HEC Changjiang Pharmaceutical Company, and

has received research funding from Seqirus. None of those research 677 funding is related to COVID-19

Correspondence and requests for materials should be addressed to M.A., and H.Y. 686 Peer review information